In 1996, Houston Methodist Hospital Department of Radiation Oncology pioneered a new approach to cancer treatment using gene therapy together with radiation therapy. As a world-class facility, Houston Methodist is one of the few locations in the country able to provide this level of care.
Research shows gene therapy helps prevent further growth of cancer cells. It can also help raise a patient’s immunity, much like a vaccine protects against a disease by building up one’s immunity to it.
To date, many patients have been treated with gene therapy and radiation with excellent results. Houston Methodist is now applying this same approach to other cancers, and soon expects to open clinical trials for patients with the following types of cancer:
Open Clinical Trial: Gene Therapy Trial for Locally Recurrent Prostate Cancer
Men who have received radiation for their prostate cancer and whose biopsy shows a recurrence may be eligible candidates for a clinical trial combining gene therapy and radiation therapy. The trial requires placement of permanent Palladium-103 seeds into the prostate gland. At the same time the radioactive seeds are placed, a gene therapy agent will be placed into the prostate gland. The patient will be required to take medication by mouth for two weeks. This medication interacts with the gene agent.
Interested patients who feel that they are potential candidates should contact Lacey McClure at 713-383-5115.